Introduction
Cholangiocarcinoma (CCA), a malignant cancer arising from bile duct epithelium, is a rare liver cancer but a serious public health problem in the northeast of Thailand as it has the highest incidence and mortality rate in the world (Sripa and Pairojkul, 2008) . Generally, only 10% of patients present with early-stage disease are considered surgical candidates (Han et al., 2005) and chemotherapy is the option left for these inoperable patients (Chou and Talalay, 1984) . However, the outcome of the chemo-drug treatment is unfavorable with the five year survival lesser than 10% (Butthongkomvong et al., 2013; Rizvi and Gores, 2013; Thunyaharn et al., 2013) . To reduce the mortality rate of CCA, new effective treatment strategies are needed.
Plant-derived compounds are gaining interest as potential cancer therapeutics (Shukla, 2007; Aras et al., 2014) , particularly for treatment-refractory cancers such as CCA (Naus et al., 2007) . In this study, tiliacorinine ( Figure. 1A), the bisbenzylisoquinoline alkaloid isolated , Sopit Wongkham 1,3 * from a tropical medicinal plant, Tiliacora triandra (Colebr.) Diels, was investigated for antitumor activity in CCA cell lines in vitro and in vivo. The molecular mechanism by which tiliacorinine induces apoptosis of CCA was also determined. Our findings suggested tiliacorinine to be a new promising compound for effective treatment against human CCA.
Materials and Methods

Chemicals and reagents
Cell culture reagents were purchased from Gibco/ Invitrogen (Carlsbad, CA). Antibodies were obtained from companies as indicated: Bcl-2-associated X protein (BAX), B-cell leukemia protein xL (Bcl xL ), X-linked inhibitor of apoptosis protein (XIAP), and poly-adenosine diphosphate ribose polymerase (PARP) from Santa Cruz Biotechnology (Santa Cruz, CA); anti-caspase-3 and-9, goat anti-rabbit IgG-and goat anti-mouse IgG-conjugated to horseradish peroxidase (HRP) from Cell Signaling Technology (Beverly, MA), and β-actin antibody from Sigma Chemical Co (St Louis, MO).
Cell lines and cell culture
Four human CCA cell lines-KKU-M055, KKU-100-KKU-M213 and KKU-M214-were established from primary tumors of CCA patients as described previously Seubwai et al., 2010) . All cells were cultured at 37°C with 5% CO 2 in Ham's F-12 containing 1% antibiotics-antimycotics solution and 10% FBS.
Isolation of tiliacorinine
Tiliacorinine was isolated from Tiliacora triandra as described previously (Pachaly and Khosravian, 1988) with modification. Briefly, 10.0 kg of pulverized dried roots and stems were macerated successively with n-hexane and ethyl acetate to give the hexane (535.20 g) and ethyl acetate (519.86 g) extracts. The plant material was then extracted with methanol-chloroform-ammonium hydroxide (15:5:1). After solvent evaporation, glacial acetic acid was added followed by ammonium hydroxide. The insoluble polymeric material was removed from the aqueous suspension and the latter was extracted with chloroform. The crude alkaloid extract was chromatographed to give tiliacorinine (1.053 g) and a mixture of minor alkaloids (300 mg). More tiliacorinine (96mg) was obtained from the ethyl acetate extract by column chromatographic separation. The spectroscopic (proton and carbon-13 NMR, and mass spectra) data were consistent with the literature values (Wiriyachitra, 1981; Pachaly and Khosravian, 1988) . Tiliacorinine was dissolved in DMSO and diluted with completed media to the indicated concentrations.
In vitro cytotoxicity test
The effects of tiliacorinine on the proliferation of CCA cells were determined using SRB assay (Skehan et al., 1990) . Briefly, CCA cells (3,000 cells/well) were incubated with tiliacorinine in a 96-well plate. At indicated time points, cells were treated with 10% ice-cold trichloroacetic acid and stained with 0.4% SRB in 1% acetic acid. The stained proteins were solubilized and the absorbance at 540nm was measured (Vichai and Kirtikara, 2006) . Dose-response curves were plotted, and the concentration of drug required to inhibit cell proliferation by 50% (IC 50 ) was calculated using the Calcusyn software (Biosoft, Oxford, UK).
DNA fragmentation assay
The isolation of fragmented DNA was carried out as previously described (Herrmann et al., 1994) . Briefly, 5×10 5 cells were lyzed in 100 µL of 10 mM Tris-HCl buffer (pH 7.4), 10 mM EDTA and 0.5% Triton X-100. Final samples were dissolved in 40 µL of Tris-EDTA buffer, pH 8.0, subjected to agarose gel electrophoresis and stained with ethidium bromide.
Acridine orange/ethidium bromide double staining
Cells (3,000 cells/100 µL) were treated with 0.01% DMSO or various concentrations of tiliacorinine for 72h and subjected to acridine orange/ethidium bromide (AO/ EB) staining as previously described (Petit et al., 1995) .
The stained cells were visualized under a fluorescent microscope (Nikon Eclipse TS100, Nikon Corporation, Tokyo, Japan). Multiple photos (9 fields/sample) were taken at randomly-selected areas and apoptotic cells were count using Image ProPlus 7.0 (Media Cybernetics, Inc., Bethesda, MD). A minimum of 100 total cells were count and expressed as a percentage. Tests were done in triplicate.
Western blotting
Cells were lyzed with RIPA buffer (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 1% NP-40) supplemented with cocktail proteinase inhibitors (Roche, Mannheim, Germany). Proteins in cell lysates were separated by a 10% SDS-polyacrylamide gel electrophoresis according to Laemmli (Laemmli, 1970) and electro-transferred onto a polyvinylidene difluoride membrane according to Bolt and Mahoney (Bolt and Mahoney, 1997) . The membrane was blocked with 1% (w/v) skim milk, 0.1% tween (v/v) in Tris-buffered saline, pH 7.4 for 30 min and incubated with specific primary antibodies at 4 o C overnight and secondary antibody conjugated-HRP at room temperature for 2h. The expression level of proteins were detected using Amersham ECL Plus Western blotting detection reagents (GE Health care, Piscataway, NJ) and captured with ImageQuant TM 400 and analyzed with ImageQuant TM TL software.
Flow cytometric analysis of apoptotic cells
Flow cytometric analysis of cell cycle distribution was performed using a FACSCalibur flow cytometer (BD-Biosciences, San Jose, CA) as previously described (Seubwai et al., 2010) . Briefly, cells were fixed with 70% ethanol at -20 o C overnight and stained with 10 μg/mL propidium iodine (PI; Sigma, St Louis, MO) in phosphate buffer saline for 30 min in the dark. A total of 10,000 cells were analyzed by flow cytometry. Sub-G1 peak was analyzed using BD FACSDiva software (BD Biosciences, San Jose, CA).
In vivo assay
Bulb/c Rag-2 Jak3 double knock-out mice (Ono et al., 2011 ) aged 8-10 week old were housed and monitored in the animal research facility according to the institutional guidelines. All experimental protocols were approved by the Institutional Animal Care and Use Committee, Kumamoto University (Kumamoto, Japan). Mice were subcutaneously injected with 4510 6 of KKU-M213 cells at both flank sides. Three days after CCA cell-injection, mice were intraperitoneally injected with 0.01% DMSO (control group; n=5) or tiliacorinine (10mg/kg body weight; n=5) once daily for 3 consecutive days. Body weights and tumor volumes were measured every 3 days. Tumors were removed and weighed 9 days after inoculation.
Statistical analysis
Experimental data were analyzed using SPSS 16.0 Windows Evaluation software (SPSS Inc., Chicago, IL). The results are presented as the mean±standard deviation of at least 3 separated experiments. Statistical significance 
Results
Tiliacorinine inhibits growth of human CCA cells
In order to determine the growth inhibitory effect of tiliacorinine on human CCA cells-KKU-M055, KKU-100, KKU-M213, and KKU-M214-cells were treated with various concentrations of tiliacorinine for 72h and investigated by SRB assay. Growth inhibitory effects of tiliacorinine on the tested cells were KKU-M055>KKU-M213>KKU-M214>KKU-100 with IC 50 values of 4.5±0.3, 5.7±0.2, 6.1±0.3, and 7.0±0.6 respectively ( Figure 1B) . Treated cells exhibited dosedependent sensitivity to tiliacorinine from 1.7-8.7 µM. As KKU-M214 and KKU-100 were less sensitive to tiliacorinine, they were selected as representative of CCA cells for the subsequent studies.
Tiliacorinine suppresses growth of human CCA cells by inducing apoptosis
We further investigated whether tiliacorinine inhibited growth of human CCA cells by induction of apoptosis. Apoptotic indices were determined by 3 different approaches. AO/EB double staining was applied to discriminate the live, apoptotic and necrotic cells. Exposure of KKU-M214 and KKU-100 cells to 4-7 µM of tiliacorinine significantly induced apoptotic cells with typical apoptotic features e.g., cell shrinkage, membrane blebbing, and chromatin condensation (Figure 2A ; left panel) in a dose-dependent manner (Figure 2A ; right panel). Number of dead cells stimulated by tiliacorinine was next validated using flow cytometric analysis with PI staining. Cells treated with tiliacorinine for 48-72h exhibited 45-60% apoptotic cells in the sub G1 peaks which were significantly higher than the controls (p<0.05; Figure 2B ). Degradation of nuclear DNA, the hallmark of apoptotic cells, was determined by DNA fragmentation assay. Cells treated with various concentrations of tiliacorinine for 24, 48, and 72h showed a gradual increase of DNA ladders, in both dose-and time-dependent manners ( Figure 2C ).
Tiliacorinine induces apoptosis through caspase activation
To determine whether tiliacorinine induced apoptosis via caspase activation, KKU-M214 was treated with IC 50 (6 µM) of tiliacorinine for 24, 48, and 72h and whole cell
Tiliacorinine reduced tumor growth in CCA xenografted mice
To investigate the antitumor activity of tiliacorinine in animal model, KKU-M213 cells were subcutaneously injected into both flanks of mice and tiliacorinine or DMSO (control group) was intraperitoneally injected once daily for 3 consecutive days, 3 days post-CCA cell-injection ( Figure 4A ). Body weights of mice from both groups were not significantly different ( Figure  4B ). One mouse in tiliacorinine treated group died on day 8 and hence all mice were sacrificed on day 9. Mean tumor volumes from tiliacorinine treated group (45.16±12.52 mm 3 ) was significantly lower than those of the control group (80.22±18.75 mm 3 ) instantly on day 3 of treatment ( Figure. 4C; p<0.001). On day 9, mean tumor weights from tiliacorinine treated group (0.07±0.02 g) was significantly lower than those of the control group (0.13±0.04 g) ( Figure 4E ; p<0.05).
Discussion
Tiliacorinine, the major alkaloid isolated from the medicinal plant-Tiliacora triandra has been proved for anti-malarial activity (Dechatiwongse et al., 1987) and antimycobacterial activity (Sureram et al., 2012) . In this study, the anticancer activity of tiliacorinine was first demonstrated in vitro and in vivo. Tiliacorinine effectively inhibited proliferation of CCA cells via induction of apoptosis and significantly reduced tumor growth in CCA xenografted mice model. These results indicate the therapeutic potential of tiliacorinine against human CCA.
Tiliacorinine inhibited growth of four human CCA cell lines with IC 50 ranging from 4.5-7.0 µM. Comparing to other natural compounds, tiliacorinine seems to be more potent than tannic acid and sesquiterpene but less effective when compared to caged xanthones. Tannic acid, a natural polyphenolic compound, inhibited proliferation of malignant human cholangiocytes with IC 50 of 60 µM (Marienfeld et al., 2003) while sesquiterpene-the lysates were subjected to western blotting. Tiliacorinine activated caspase-3, -9 and PARP cleavages in a timedependent fashion ( Figure 3A ). In addition, tiliacorinine significantly increased expression of a proapoptotic protein, BAX, and decreased expression of antiapoptotic proteins, XIAP and Bcl xL , in a time-dependent manner ( Figure 3B ). DOI:http://dx.doi.org/10.7314/APJCP.2014.15.17.7473 derivative of zerumbone-showed antiproliferative activity against KKU-100 cell line with an IC 50 of 16.44 µM (Songsiang et al., 2010) . The growth inhibitory effect of four caged xanthones-isomorellin, isomorellinol, forbesione and gambogic acid-on KKU-100 showed IC 50 ranging from 0.11-2.64 µM (Hahnvajanawong et al., 2010) .
In vitro and In vivo Antitumor Activity of Tiliacorinine in Human Cholangiocarcinoma
Tiliacorinine exhibited antiproliferative activity on CCA cell lines as time-and dose-dependent manners, with a narrow range of 4.0-7.5 µM at 72h. Comparing to other CCA cell lines, KKU-100 was the less sensitive cell line toward most of conventional chemotherapeutic agent tested (Tepsiri et al., 2005) . KKU-100 exhibited the IC 50 of 5-fluorouracil, mitomycin-C, paclitaxel and cisplatin = 1,018 µM, 45 µM, 39 µM and 37 µM, respectively. KKU-100, however, was sensitive to tiliacorinine with the IC 50 of 7 µM which was similar to other CCA cell lines. This highlights tiliacorinine as a potent agent for CCA treatment.
Tiliacorinine inhibited CCA cell growth by inducing apoptosis as evidenced by the results from three different assays. First, tiliacorinine treatment increased number of apoptotic cells as determined by AO/EB staining. Second, DNA ladder, the hallmark of apoptosis revealed by DNA fragmentation assay was clearly demonstrated in cells treated with tiliacorinine. Third, tiliacorinine treated cells significantly increased apoptotic cells in sub G1 peak as demonstrated by flow cytometry. Induction of apoptosis has been considered to be the major mechanism of anticancer drug discovery (Reed, 2001 ).
The molecular mechanism by which tiliacorinine induced apoptosis was shown to be via activation of caspase-3, -9, and consequently PARP cleavage. Tiliacorinine also up-regulated BAX, a proapoptotic protein, and down-regulated XIAP and Bcl xL in human CCA cells. Induction of apoptosis via caspase-activation pathways seems to be the general mechanisms of anticancer agents from natural compounds, such as cepharanthine, a biscoclaurine alkaloid from roots of Stephania cepharantha Hayata (Wu et al., 2001; Seubwai et al., 2010) , emodin, an anthraquinone derivative (Yaoxian et al., 2013) and berberine, an isoquinoline alkaloid (Yip and Ho, 2013) .
Several attempts have been made to find new agents that effectively inhibited growth and metastatsis of CCA, however, most of them demostrated the effects in vitro, e.g., diethyldithiocarbamate (Srikoon et al., 2013) , histone deacetylase inhibitors (Sriraksa and Limpaiboon, 2013) . The antitumor activity of tiliacorinine was obviously demonstrated in CCA cell lines and CCA xenografted mice. Tumor volumes and tumor weights of tiliacorinine treated group were 2 folds reduced compared to the control group. Tiliacorinine appeared to have a rapid antitumor activity as it was administrated only 3 consecutive days after CCA cell-injection and the tumor volume was significantly reduced instantly. As this study was the first report on the antitumor activity of tiliacorinine in the xenografted mouse model, the pharmaco-kinetic, drug safety and efficacy of tiliacorinine have to be investigated cautiously.
The abundance of literature suggests that defects along apoptotic pathways play a crucial role in carcinogenesis and that many new treatment strategies targeting apoptosis are feasible for the treatment of various cancers (Wong, 2011; Sankari et al., 2012) . Additionally, almost clinically used anticancer drugs are aimed to activate apoptosis of tumor cells (Hadi et al., 2000) . In this study, tiliacorinine showed apoptotic effect on human CCA cells and suppressed tumor growth in CCA xenografted mice, suggesting this auspicious alkaloid an effective agent for CCA treatment. Nevertheless, further intensive study in safety and efficacy of tiliacorinine is highly recommended. Furthermore, to overcome cancer by achieving synergistic therapeutic effect, reducing toxicity, and minimizing the drug resistance (Chou, 2010) , further study on drug combination between tiliacorinine and the conventional chemotherapeutic drugs is encouraged.
